Home | News | Events | Contact Us | English | 繁體中文 | 日本語
About Us Product & Service Facilities Quality & Compliance For Investors Career
Latest Events
Latest News
Product & Service
CPhI Japan, Tokyo, Japan
Apr. 14-16, 2021
DCAT Week, New York
Jul. 12-15, 2021
TW Patent No. I718533 entitled PREPARATION METHOD OF RIBOCICLIB AND ITS SALT AND CRYSTALLINE FORM THEREOF was granted on Feb 11, 2021. 2021-02-26
Filed US DMF of Ferric Carboxymaltose (#035442, date of submission: Dec. 31, 2020) 2021-01-05
Filed US DMF of Eribulin Mesylate (#035358, date of submission: Nov. 30, 2020) 2021-01-05
US Patent No.US10766900B2 entitled Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof was granted on Sep 8, 2020. 2020-09-30
Formosa Labs and Fresenius Kabi enter into a Registration and Distribution Agreement for a breast cancer chemotherapy injection. 2020-09-16
Active Pharmaceutical Ingredients
Contract Development and Manufacturing Organization (CDMO)
Antibody Drug Conjugates (ADCs)
Injectable Manufacturing Services



 
Copyright ©2014 Formosa Laboratories, Inc. All Rights Reserved.
丙肝